BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23161364)

  • 1. p53 acetylation enhances Taxol-induced apoptosis in human cancer cells.
    Kim JH; Yoon EK; Chung HJ; Park SY; Hong KM; Lee CH; Lee YS; Choi K; Yang Y; Kim K; Kim IH
    Apoptosis; 2013 Jan; 18(1):110-20. PubMed ID: 23161364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors.
    Terui T; Murakami K; Takimoto R; Takahashi M; Takada K; Murakami T; Minami S; Matsunaga T; Takayama T; Kato J; Niitsu Y
    Cancer Res; 2003 Dec; 63(24):8948-54. PubMed ID: 14695212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways.
    Meng J; Zhang HH; Zhou CX; Li C; Zhang F; Mei QB
    Oncol Rep; 2012 Jul; 28(1):384-8. PubMed ID: 22552631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
    Zhou J; O'brate A; Zelnak A; Giannakakou P
    Cancer Res; 2004 Dec; 64(23):8708-14. PubMed ID: 15574781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells.
    Roy S; Packman K; Jeffrey R; Tenniswood M
    Cell Death Differ; 2005 May; 12(5):482-91. PubMed ID: 15746940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.
    Zhu WG; Lakshmanan RR; Beal MD; Otterson GA
    Cancer Res; 2001 Feb; 61(4):1327-33. PubMed ID: 11245429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment.
    Fan S; Cherney B; Reinhold W; Rucker K; O'Connor PM
    Clin Cancer Res; 1998 Apr; 4(4):1047-54. PubMed ID: 9563901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC inhibitor DWP0016 activates p53 transcription and acetylation to inhibit cell growth in U251 glioblastoma cells.
    Jin H; Liang L; Liu L; Deng W; Liu J
    J Cell Biochem; 2013 Jul; 114(7):1498-509. PubMed ID: 23297003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).
    Zhao Y; Lu S; Wu L; Chai G; Wang H; Chen Y; Sun J; Yu Y; Zhou W; Zheng Q; Wu M; Otterson GA; Zhu WG
    Mol Cell Biol; 2006 Apr; 26(7):2782-90. PubMed ID: 16537920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
    Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
    Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylated and hypoacetylated mutant p53 enhances cisplatin-induced apoptosis through caspase-9 pathway in the absence of transcriptional activation or translation.
    Lai MD; Lin WC; Sun YM; Chang FL
    Int J Mol Med; 2005 Apr; 15(4):725-34. PubMed ID: 15754039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells.
    Choi YH; Yoo YH
    Oncol Rep; 2012 Dec; 28(6):2163-9. PubMed ID: 23023313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.
    Giannakakou P; Robey R; Fojo T; Blagosklonny MV
    Oncogene; 2001 Jun; 20(29):3806-13. PubMed ID: 11439344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer.
    Shankar S; Srivastava RK
    Int J Oncol; 2007 Apr; 30(4):905-18. PubMed ID: 17332930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
    Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
    Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner.
    Stewart ZA; Tang LJ; Pietenpol JA
    Oncogene; 2001 Jan; 20(1):113-24. PubMed ID: 11244509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxol induction of p21WAF1 and p53 requires c-raf-1.
    Blagosklonny MV; Schulte TW; Nguyen P; Mimnaugh EG; Trepel J; Neckers L
    Cancer Res; 1995 Oct; 55(20):4623-6. PubMed ID: 7553639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Taxol-induced cell death are concentration dependent.
    Torres K; Horwitz SB
    Cancer Res; 1998 Aug; 58(16):3620-6. PubMed ID: 9721870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Id-1 regulates Bcl-2 and Bax expression through p53 and NF-kappaB in MCF-7 breast cancer cells.
    Kim H; Chung H; Kim HJ; Lee JY; Oh MY; Kim Y; Kong G
    Breast Cancer Res Treat; 2008 Nov; 112(2):287-96. PubMed ID: 18158619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.